<code id='ACB2B34342'></code><style id='ACB2B34342'></style>
    • <acronym id='ACB2B34342'></acronym>
      <center id='ACB2B34342'><center id='ACB2B34342'><tfoot id='ACB2B34342'></tfoot></center><abbr id='ACB2B34342'><dir id='ACB2B34342'><tfoot id='ACB2B34342'></tfoot><noframes id='ACB2B34342'>

    • <optgroup id='ACB2B34342'><strike id='ACB2B34342'><sup id='ACB2B34342'></sup></strike><code id='ACB2B34342'></code></optgroup>
        1. <b id='ACB2B34342'><label id='ACB2B34342'><select id='ACB2B34342'><dt id='ACB2B34342'><span id='ACB2B34342'></span></dt></select></label></b><u id='ACB2B34342'></u>
          <i id='ACB2B34342'><strike id='ACB2B34342'><tt id='ACB2B34342'><pre id='ACB2B34342'></pre></tt></strike></i>

          explore

          explore

          author:comprehensive    Page View:1359
          James Comer (R-KY) walks on the House side of the U.S. Capitol on May 14, 2024 in Washington, DC
          Rep. James Comer (R-Ky.), the chair of the House Committee on Oversight and Accountability, has taken an interest in pharmacy benefit managers. Kent Nishimura/Getty Images

          WASHINGTON — Executives from the three major pharmacy benefit manager companies have been invited to testify before the House Committee on Oversight and Accountability next month, four sources familiar with the planning told STAT.

          Executives from Optum, CVS Caremark, and Express Scripts, owned by Cigna, were asked to testify before the panel on June 4.

          advertisement

          The committee and companies did not respond to requests for comment.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          The Supreme Court will review a ruling striking down a domestic violence federal gun ban
          The Supreme Court will review a ruling striking down a domestic violence federal gun ban

          WASHINGTON--TheSupremeCourtwillreviewarulingstrikingdownadomesticviolencefederalgunban.

          read more
          ASCO Daily Recap: CAR
          ASCO Daily Recap: CAR

          AdobeYou’rereadingthewebeditionofASCOin30Seconds,STAT’sguidetotheAmericanSocietyofClinicalOncologyan

          read more
          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more

          Novartis is flashing warning signs about its newly acquired myelofibrosis drug

          MollyFerguson/STATCHICAGO—SomethingisoffaboutthewayNovartisistalkingaboutpelabresib,itsnewlyacquired